# Survival with Osimertinib plus Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/survival-with-osimertinib-plus-chemotherapy-in-i-egfr-i-mutated-advanced-nsclc/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Pasi A. Jänne,David Planchard,Kunihiko Kobayashi,James Chih‐Hsin Yang,Ying L. Liu,Natalia Valdiviezo,Tae Min Kim,Liyan Jiang,Hiroshi Kagamu,Noriko Yanagitani,Jialei Wang,Bivas Biswas,Artem Poltoratskiy,Yeni Nerón,Carlos A. Rojas,Leona Koubková,Carles Escriu,Doreen A. Ezeife,Helen Mann,Elena Armenteros-Monterroso,Yuri Rukazenkov,Chee Khoon Lee |
| Citations | 80 |
| DOI | 10.1056/nejmoa2510308 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W4415295904 |
| PMID | 41104938 |
| Type | article |
| Year | 2025 |

## Paper authors

- [Bivas Biswas](https://scholariq.org/researchers/bivas-biswas/)

## Paper journal

- [New England Journal of Medicine](https://scholariq.org/journals/new-england-journal-of-medicine/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Fibroblast Growth Factor Research](https://scholariq.org/topics/fibroblast-growth-factor-research/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.